Atorvin Dosage/Direction for Use

May be taken at any time of the day with or without food.
Adult & Geriatric: Primary prevention: Dose should be individualized according to baseline LDL-cholesterol and patient response; adjustment should be made at intervals of 2 to 4 weeks (4 weeks in pediatric).
Hypercholesterolemia (heterozygous familial, nonfamilial and mixed hyperlipidemia (Fredrickson type IIa and IIb): initial 10-20 mg once daily; patients requiring >45% reduction in LDL-C may be started at 40 mg once daily; range 10-80 mg once daily.
Homozygous familial hypercholesterolemia: 10-80 mg once daily.
ACC/AHA blood cholesterol guideline recommendations: adult >21 years: Primary prevention: LDL-C ≥190 mg/dL: high intensity therapy 80 mg once daily; if unstable to tolerate, may reduce dose to 40 mg once daily.
Type 1 or 2 diabetes, age 40-75 years: moderate intensity therapy: 10-20 mg once daily.
Type 1 or 2 diabetes, age 40-75 years and an estimated 10-year ASCVD risk ≥7.5%: high intensity statin therapy 80 mg once daily.
Age 40-75 years and an estimated 10-year ASCVD risk ≥7.5%: moderate to high intensity statin therapy 10-80 mg once daily.
Secondary prevention: Patient has ASCVD (e.g. Coronary heart disease, stroke/TIA or peripheral arterial disease) and: Age ≤75 years: high intensity therapy 80 mg once daily; if unable to tolerate, may reduce dose to 40 mg once daily.
Age >75 years or not a candidate for high intensity statin therapy: moderate intensity therapy 10-20 once daily.
Pediatric: 10-17 years (females postmenarche) for HeFH: Initial 10 mg once daily (max dose 20 mg once daily).
Dosage adjustment for atorvastatin with concomitant medications: Boceprevir, nelfinavir: use lowest effective atorvastatin dose (not to exceed 40 mg daily).
Clarithromycin, itraconazole, fosamprenavir, ritonavir (plus darunavir, fosamprenavir or saquinavir): use lowest effective atorvastatin dose (not to exceed 20 mg daily).
Lomitapide: consider atorvastatin dose reduction.
Renal impairment: No dosage adjustment necessary.
Hepatic impairment: Contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.